Cortechs.ai, a company specializing in AI-driven medical imaging solutions, has launched the latest version of its NeuroQuant Brain Tumor software. This FDA-approved tool now offers fully automated segmentation and volumetric analysis specifically for brain metastases and meningiomas. Designed to assist radiologists, neuro-oncologists, neurosurgeons, and other healthcare professionals, the software supports standard diagnostic workflows by automatically identifying and measuring brain tumors confirmed as cancer, helping clinicians work more efficiently.
Health Technology Insights: Proprio Joins the AWS Partner Network
The new AI models enhance NeuroQuant® Brain Tumor’s existing glioma detection features by adding the capability to segment and quantify brain metastases and meningiomas. Available through a secure cloud platform, the software integrates smoothly with hospital PACS systems, enabling easy access and rapid adoption across healthcare organizations. This update aims to improve diagnostic accuracy, consistency, and efficiency by delivering precise volumetric reports and clear segmentations.
Additionally, the software supports long-term tracking of tumor changes, allowing clinicians to monitor treatment effectiveness and disease progression—critical factors for improving patient care. The release also includes features that allow segmentation results to be directly imported into radiation oncology and neurosurgery planning systems. This eliminates manual contouring, promotes better collaboration between departments, and accelerates treatment planning and follow-up evaluations.
Health Technology Insights: DXC Assure Risk Management Launches AI Claims Solution
Experts have praised these advancements. Dr. Nikdokht Farid, a neuroradiologist at UC San Diego, stated, “NeuroQuant Brain Tumor’s ability to track changes in tumor volume over time offers important insights into how well treatments are working and helps make better clinical decisions. The latest software release, which provides automated segmentation and tracking of brain metastases and meningiomas, has great potential to improve workflow and clinical confidence in detecting, measuring, and following these tumors.”
Kyle Frye, CEO of Cortechs.ai, said, “We’re delivering advanced AI technology that changes how clinicians handle difficult diagnostic challenges. This isn’t just another tool — it’s a powerful system that gives healthcare professionals new capabilities. We’re continuing to bring together the entire care process, including radiology, surgery, and oncology, with our latest version of NeuroQuant Brain Tumor.” Nate White, CTO, added, “Our technology turns hours of manual work into minutes of precise, automated analysis. This isn’t just about being efficient — it’s about giving clinicians the tools and information needed to provide better patient care while making workflows more efficient in struggling healthcare systems.” NeuroQuant Brain Tumor is the first FDA-approved cloud-based software that offers automated volumetric segmentation of brain metastases and meningiomas in clinical settings. This update builds on Cortechs.ai’s expertise in glioma tracking and brain volumetrics, creating a unified, scalable neuroimaging platform that supports seamless integration into neurosurgery and neuro-oncology workflows to improve treatment planning, speed up response assessment, and deliver consistent, high-quality care.
Health Technology Insights: Panome Bio Multi-omics Laboratory Enhances Clinical Capabilities with CLIA Certification
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
